Search research articles
Contact Us
Filters
Showing results (11-20 of 203) with videos related to
Page
of 21
Sort By:
Breast Cancer Research and Treatment
|
April 25, 2024
Unveiling the potential of breast MRI: a game changer for BI-RADS 4A microcalcifications
Shiping Li, Yihao Lin, Guangyu Liu, et al.
Molecular Medicine Reports
|
October 11, 2024
[Corrigendum] Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF‑1 pathway inhibition <i>in vivo</i>
Xiaoqing Jia, Jingyi Cheng, Zhenzhou Shen, et al.
Molecular Medicine Reports
|
February 3, 2018
Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo
Xiaoqing Jia, Jingyi Cheng, Zhenzhou Shen, et al.
Plos One
|
June 23, 2011
Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials
Wenjin Yin, Yiwei Jiang, Zhenzhou Shen, et al.
Current Cancer Drug Targets
|
April 27, 2016
CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma
Xiaoqing Jia, Guangyu Liu, Jingyi Cheng, et al.
Plos One
|
September 5, 2014
Similar prognoses for invasive micropapillary breast carcinoma and pure invasive ductal carcinoma: a retrospectively matched cohort study in China
Yin Liu, Xiaoyan Huang, Rui Bi, et al.
Oncotargets and Therapy
|
October 8, 2015
Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes
Kai Yin, Liheng Zhou, Zhimin Shao, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 1, 2010
An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer
Wen Chen, Zefei Jiang, Zhimin Shao, et al.
Cancer Science
|
August 13, 2010
Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells
Chuandong Ma, Xiuqing Niu, Jianmin Luo, et al.
Nanotechnology
|
July 2, 2024
Highly-efficient low-cost polarization-sensitive organic photodetectors based on laminated self-assembly planar and bulk heterojunctions
Chi Zhang, Zhimin Shao, Feng Yu, et al.
Page
of 21
Search research articles
Search
Showing results (11-20 of 203) with videos related to
Sort By:
Page
of 21
Breast Cancer Research and Treatment
|
April 25, 2024
Unveiling the potential of breast MRI: a game changer for BI-RADS 4A microcalcifications
Shiping Li, Yihao Lin, Guangyu Liu, et al.
Molecular Medicine Reports
|
October 11, 2024
[Corrigendum] Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF‑1 pathway inhibition <i>in vivo</i>
Xiaoqing Jia, Jingyi Cheng, Zhenzhou Shen, et al.
Molecular Medicine Reports
|
February 3, 2018
Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo
Xiaoqing Jia, Jingyi Cheng, Zhenzhou Shen, et al.
Plos One
|
June 23, 2011
Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials
Wenjin Yin, Yiwei Jiang, Zhenzhou Shen, et al.
Current Cancer Drug Targets
|
April 27, 2016
CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma
Xiaoqing Jia, Guangyu Liu, Jingyi Cheng, et al.
Plos One
|
September 5, 2014
Similar prognoses for invasive micropapillary breast carcinoma and pure invasive ductal carcinoma: a retrospectively matched cohort study in China
Yin Liu, Xiaoyan Huang, Rui Bi, et al.
Oncotargets and Therapy
|
October 8, 2015
Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes
Kai Yin, Liheng Zhou, Zhimin Shao, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 1, 2010
An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer
Wen Chen, Zefei Jiang, Zhimin Shao, et al.
Cancer Science
|
August 13, 2010
Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells
Chuandong Ma, Xiuqing Niu, Jianmin Luo, et al.
Nanotechnology
|
July 2, 2024
Highly-efficient low-cost polarization-sensitive organic photodetectors based on laminated self-assembly planar and bulk heterojunctions
Chi Zhang, Zhimin Shao, Feng Yu, et al.
Page
of 21